Author

Ramiro G. Banda Elizondo

Observed name: Ramiro G Banda Elizondo

OpenAlex ID: A5113965516

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

2021 · Stefano Del Prato, Steven E Kahn, et al. · The Lancet · 748

Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial

2026 · Rodica Pop-Busui, Søren Rasmussen, et al. · JAMA Internal Medicine · 18

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial

2026 · Sharon L. Mulvagh, Silvio E. Inzucchi, et al. · JAMA Cardiology · 6

First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial

2026 · Nikolaus Marx, John E. Deanfield, et al. · JAMA Cardiology

Works count: 4

Citation count: 772

H-index: 3

I10-index: 2